Dural sealant to enter pivotal US trial:
This article was originally published in Clinica
Executive Summary
Confluent Surgical is to start a pivotal US study of its dural sealant for preventing cerebrospinal fluid (CSF) leaks, which are associated with neurosurgical and spinal orthopaedic procedures. The FDA has given the Waltham, Massachusetts firm the go-ahead to test its product - DuraSeal - as an adjunct to dural closure in a prospective, multicentre study. As for plans to market the product outside the US, Confluent intends to use results from a recently announced assessment to support an application to CE-mark and launch the product in Europe. The data revealed a 100% intraoperative and 96% post-operative success rate in preventing CSF leak, the company said.
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.